HUP0303523A2 - Csökkentett immunogenitású, módosított inzulin - Google Patents
Csökkentett immunogenitású, módosított inzulinInfo
- Publication number
- HUP0303523A2 HUP0303523A2 HU0303523A HUP0303523A HUP0303523A2 HU P0303523 A2 HUP0303523 A2 HU P0303523A2 HU 0303523 A HU0303523 A HU 0303523A HU P0303523 A HUP0303523 A HU P0303523A HU P0303523 A2 HUP0303523 A2 HU P0303523A2
- Authority
- HU
- Hungary
- Prior art keywords
- modified
- insulin
- subject
- polypeptides
- modified insulin
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 5
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 230000002163 immunogen Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000008105 immune reaction Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A találmány tárgyát olyan polipeptidek képezik, amelyek - elsősorbanterápiás célból speciálisan embereknek adagolhatók. A találmányszerinti polipeptidek módosított polipeptidek, mely módosításeredményeként a polipeptid - embereknek történő adagolása esetén -kevésbé hajlamos immunreakció kiváltására. Közelebbről, a találmánytárgyát humán inzulin módosított változatai képezik, mely inzulin-proteinváltozatok in vivo alkalmazáskor lényegében nem immunogénekvagy kevésbé immunogének, mint a megfelelő, módosítás nélküli alakjuk.Szintén a találmány tárgyát képezik a nem módosított proteinbőlszármazó T-sejt-epitóp peptidek, valamint azok alkalmazása csökkentimmunogenitású, módosított inzulinváltozatok előállítására. Atalálmány tárgyát képezik továbbá a találmány szerinti módosítottinzulinmolekulákat kódoló DNS-ek, a találmány szerinti módosítottinzulinmolekulákat tartalmazó gyógyászati készítmények, valaminteljárások a módosított inzulinmolekulák előállítására. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01106900 | 2001-03-20 | ||
| PCT/EP2002/003015 WO2002074808A2 (en) | 2001-03-20 | 2002-03-19 | Modified insulin with reduced immunogenicity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0303523A2 true HUP0303523A2 (hu) | 2004-01-28 |
| HUP0303523A3 HUP0303523A3 (en) | 2005-12-28 |
Family
ID=8176848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0303523A HUP0303523A3 (en) | 2001-03-20 | 2002-03-19 | Modified insulin with reduced immunogenicity |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040096459A1 (hu) |
| EP (1) | EP1412385A2 (hu) |
| JP (1) | JP2004533817A (hu) |
| KR (1) | KR20030085007A (hu) |
| CN (1) | CN1524090A (hu) |
| BR (1) | BR0208120A (hu) |
| CA (1) | CA2441388A1 (hu) |
| HU (1) | HUP0303523A3 (hu) |
| MX (1) | MXPA03008402A (hu) |
| PL (1) | PL369309A1 (hu) |
| RU (1) | RU2003130060A (hu) |
| WO (1) | WO2002074808A2 (hu) |
| ZA (1) | ZA200308061B (hu) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1781685A4 (en) * | 2004-07-23 | 2008-06-25 | Inst Medical W & E Hall | THERAPEUTIC AND DIAGNOSTIC AGENTS |
| US20090271021A1 (en) * | 2008-04-28 | 2009-10-29 | Popp Shane M | Execution system for the monitoring and execution of insulin manufacture |
| GB2574561A (en) * | 2017-03-14 | 2019-12-11 | Univ California | Engineering CRISPR CAS9 immune stealth |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| DE69833755T2 (de) * | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| GB9712892D0 (en) * | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
| EP1051432B1 (en) * | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
-
2002
- 2002-03-19 EP EP02726186A patent/EP1412385A2/en not_active Withdrawn
- 2002-03-19 HU HU0303523A patent/HUP0303523A3/hu unknown
- 2002-03-19 RU RU2003130060/04A patent/RU2003130060A/ru not_active Application Discontinuation
- 2002-03-19 BR BR0208120-2A patent/BR0208120A/pt not_active IP Right Cessation
- 2002-03-19 JP JP2002573815A patent/JP2004533817A/ja active Pending
- 2002-03-19 CN CNA028062620A patent/CN1524090A/zh active Pending
- 2002-03-19 KR KR10-2003-7012145A patent/KR20030085007A/ko not_active Application Discontinuation
- 2002-03-19 CA CA002441388A patent/CA2441388A1/en not_active Abandoned
- 2002-03-19 MX MXPA03008402A patent/MXPA03008402A/es unknown
- 2002-03-19 WO PCT/EP2002/003015 patent/WO2002074808A2/en not_active Application Discontinuation
- 2002-03-19 PL PL02369309A patent/PL369309A1/xx unknown
- 2002-03-19 US US10/473,633 patent/US20040096459A1/en not_active Abandoned
-
2003
- 2003-10-16 ZA ZA200308061A patent/ZA200308061B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03008402A (es) | 2004-01-29 |
| ZA200308061B (en) | 2004-07-14 |
| CN1524090A (zh) | 2004-08-25 |
| WO2002074808A2 (en) | 2002-09-26 |
| US20040096459A1 (en) | 2004-05-20 |
| KR20030085007A (ko) | 2003-11-01 |
| JP2004533817A (ja) | 2004-11-11 |
| BR0208120A (pt) | 2004-03-09 |
| HUP0303523A3 (en) | 2005-12-28 |
| CA2441388A1 (en) | 2002-09-26 |
| WO2002074808A3 (en) | 2004-02-26 |
| RU2003130060A (ru) | 2005-04-10 |
| PL369309A1 (en) | 2005-04-18 |
| EP1412385A2 (en) | 2004-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0401534A2 (hu) | Módosított humán IX. faktor | |
| HUP0400700A2 (hu) | Csökkentett immunogenitású, módosított humán agyi eredetű neutróf faktor (BDNF) | |
| NO20076239L (no) | Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom | |
| HUP0402071A2 (hu) | Csökkentett immunogenitású, módosított leptin | |
| HUP0400703A2 (hu) | Csökkentett immunogenitású módosított eritropoietin (EPO) | |
| HUP0203409A2 (hu) | Gamma-interferon-konjugátumok | |
| NO20015584L (no) | Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling | |
| HUP0400698A2 (hu) | Csökkentett immunogenitású módosított interleukin-1-receptor-antagonista (IL-1RA) | |
| HUP0303534A2 (hu) | Csökkent immunogenitású módosított interferon-béta | |
| PL371278A1 (en) | Modified factor viii | |
| HUP0303430A2 (hu) | Csökkentett immunogenitású, módosított protamin | |
| WO2002098360A3 (en) | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease | |
| HUP0102479A2 (hu) | Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek | |
| HUP0500637A2 (hu) | Neublasztin polimer konjugátumai és alkalmazási eljárásai | |
| HUP0402334A2 (hu) | Módosított humán növekedési hormon | |
| EP1556513A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS | |
| HUP0401121A2 (hu) | Csökkentett immunogenitású, módosított trombopoietin (TPO) | |
| HUP0303150A2 (hu) | Csökkentett immunogenitású, módosított keratinocita növekedési faktor (KGF) | |
| HUP0303309A2 (hu) | Csökkentett immunogenitású módosított interferon-alfa | |
| WO2003039591A3 (de) | Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle | |
| HUP0402041A2 (hu) | Csökkentett immunogenitású, módosított granulocita-kolonizációt stimuláló faktor (G-CSF) | |
| HUP0303523A2 (hu) | Csökkentett immunogenitású, módosított inzulin | |
| HUP0303310A2 (hu) | Csökkentett immunogenitású módosított ciliáris neurotrofikus faktor (CNTF) | |
| DK1173476T3 (da) | Funktionelle sojabönneproteiner | |
| HUP0302566A2 (hu) | Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |